reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

ENvue Medical, Inc.

FEED · Nasdaq

3 reporting failures in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 13.1% of the time, against 4.0% for companies with a clean record.

$7Mpublic float
2026-08-14most recent failure

Score over time

01234202220232024202520262022-01-01 · score 22021-05-17 filed late (10-Q) · accounts not ready2021-03-31 filed late (10-K) · accounts not ready2022-04-01 · score 22022-03-31 filed late (10-K) · accounts not ready2021-05-17 filed late (10-Q) · accounts not ready2022-07-01 · score 12022-03-31 filed late (10-K) · accounts not ready2022-10-01 · score 12022-03-31 filed late (10-K) · accounts not ready2023-01-01 · score 12022-03-31 filed late (10-K) · accounts not ready2023-04-01 · score 12023-03-31 filed late (10-K) · accounts not ready2023-07-01 · score 12023-03-31 filed late (10-K) · accounts not ready2023-10-01 · score 12023-03-31 filed late (10-K) · accounts not ready2024-01-01 · score 22023-12-11 auditor change2023-03-31 filed late (10-K) · accounts not ready2024-04-01 · score 12023-12-11 auditor change2024-07-01 · score 22024-04-01 filed late (10-K) · accounts not ready2023-12-11 auditor change2024-10-01 · score 22024-04-01 filed late (10-K) · accounts not ready2023-12-11 auditor change2025-01-01 · score 12024-04-01 filed late (10-K) · accounts not ready2025-04-01 · score 12024-04-01 filed late (10-K) · accounts not ready2025-07-01 · score 12025-05-15 filed late (10-Q) · accounts not ready2025-10-01 · score 32025-08-14 filed late (10-Q) · accounts not ready2025-08-14 auditor change2025-05-15 filed late (10-Q) · accounts not ready2026-01-01 · score 32025-08-14 filed late (10-Q) · accounts not ready2025-08-14 auditor change2025-05-15 filed late (10-Q) · accounts not ready2026-04-01 · score 42026-03-31 filed late (10-K) · accounts not ready2025-08-14 filed late (10-Q) · accounts not ready2025-08-14 auditor change2025-05-15 filed late (10-Q) · accounts not ready2026-07-01 · score 42026-05-15 filed late (10-Q) · accounts not ready2026-03-31 filed late (10-K) · accounts not ready2025-08-14 filed late (10-Q) · accounts not ready2025-08-14 auditor change2026-10-01 · score 32026-08-14 filed late (10-Q) · accounts not ready2026-05-15 filed late (10-Q) · accounts not ready2026-03-31 filed late (10-K) · accounts not ready

Hover or tap a dot to see the filings behind that score.

Why they said they were late

ENvue Medical, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date

NT 10-Q, filed 2026-08-14 · accounts not ready

What it filed

2026-08-14filed late (10-Q)accounts not ready SEC →

ENvue Medical, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date

2026-05-15filed late (10-Q)accounts not ready SEC →

ENvue Medical, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date

2026-03-31filed late (10-K)accounts not ready SEC →

ENvue Medical, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) within the time period, as the Company requires additional time to review the information required to be included in the Form 10-K, including the financial statements, for the fourth quarter and fiscal year ended December 31, 2025. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended

2025-08-14filed late (10-Q)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date

2025-08-14auditor changed or resigned SEC →

2025-05-15filed late (10-Q)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete its financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date

2024-04-01filed late (10-K)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) within the time period, as the Company requires additional time to review the information required to be included in the Form 10-K, including the financial statements, for the fourth quarter and fiscal year ended December 31, 2023. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended

2023-12-11auditor changed or resigned SEC →

2023-03-31filed late (10-K)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”) within the time period due to delays in compiling information required to be included in the Form 10-K, including information relating to the preparation and audit of its financial statements. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended

2022-03-31filed late (10-K)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”) within the time period due to delays in compiling information required to be included in the Form 10-K, including information relating to the preparation and audit of its financial statements. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended

2021-05-17filed late (10-Q)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Form 10-Q”) within the time period due to the observance of an intervening religious holiday during which management will be unavailable to finalize the financial information contained in the Form 10-Q. The Company expects to file the Form 10-Q within the extension period of 5 calendar days, as provided under Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended

2021-03-31filed late (10-K)accounts not ready SEC →

NanoVibronix, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Form 10-K”) within the time period for the reasons described below. As previously disclosed in the Company’s proxy statement filed with the SEC on March 3, 2021, the Company has scheduled a special meeting of stockholders (the “Special Meeting”) on March 31, 2021 to consider and act upon (i) a proposal to ratify an increase in the number of authorized shares of the Company’s common stock, $0.001 par value (“Common Stock”) from 20,000,000 to 24,109,635 shares, effective as of December 4, 2020, and to further ratify the issuance of such shares upon conversion and exercise of certain of the Company’s securities as described in the proxy statement (the “Share Increase Ratification”) and (ii) a proposal to increase the number of shares of Common Stock which the Company is authorized to issue to 45,000,000 shares. The Company convened and immediately adjourned the Special Meeting to provide more time to solicit and obtain votes regarding the foregoing proposals. The Special Meeting is scheduled to reconvene on April 14, 2021. As the results of the Special Meeting, including whether approval of the Share Increase Ratification is secured, will have a material impact on the Company’s disclosure in the Form 10-K and the financial statements included therein, the Company believes such information should be included in the Form 10-K at the time it is filed. Due to the adjournment of the Special Meeting and the related implications, the Company will be unable to complete and file the Form 10-K without unreasonable effort or expense. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com